The integration of cardiac biomarkers, particularly NT‐proBNP, high‐sensitivity troponin I, and C‐reactive protein, significantly enhanced mortality risk prediction beyond traditional clinical variables, supporting their incorporation into routine clinical assessment of AF patients in CCU settings. Here, NPPB is linked to atrial fibrillation.